cardiogenic shock

FDA Review: Abiomed, Mallinckrodt, Aro and More
BioSpace
Sun, 09/18/22 - 10:42 pm
FDA
devices
Medtech
Abiomed
cardiogenic shock
clinical trials
Impella
Mallinckrodt
Kymera Therapeutics
Aro Biotherapeutics
Windtree's phase 2 shock med rapidly raises blood pressure—and share price
Fierce Biotech
Wed, 04/20/22 - 11:21 pm
Windtree Therapeutics
cardiogenic shock
istaroxime
Abiomed touts new Impella study results
Medical Design and Outsourcing
Fri, 04/5/19 - 11:32 pm
Abiomed
Impella
cardiogenic shock
devices